A Study to Analyze the Effects of Buprenorphine on Hyperalgesia in Patients with Opioid Use Disorder

Overview

About this study

The purpose of this study is to investigate the effects of buprenorphine on hyperalgesia (HP) perception in adults undergoing treatment for opioid use disorder (OUD).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Please contact the study team to discuss whether or not you are eligible to participate in a study.

Inclusion Criteria:

  • Age 18 to 70 years old.
  • Diagnosis of opioid use disorder.
  • Stable dose of buprenorphine or methadone for 7 days.
  • No pharmacotherapy for OUD for 7 days for individuals in the no pharmacotherapy group.

Exclusion Criteria

  • Medical or surgical conditions that could be adversely impacted by HP testing including, but not exclusively limited to, active psoriatic lesions at the site of testing, cellulitis at site of testing, and previous skin grafting at site of testing. Patients may be excluded for other comorbid medical or surgical conditions based on the physician investigator’s discretion.
  • History of schizophrenia, dementia, or other chronic psychiatric disorder that could be adversely impacted by study participation. Patients may be excluded for other comorbid mental health conditions based on the physician investigator’s discretion.
  • Inability to function independently in an ambulatory care setting due to severe deconditioning requiring use of supportive gait aids including a cane or walker.  Patients may be excluded for other functional problems based on the physician investigator’s discretion.
  • Signs and symptoms of opioid withdrawal syndrome.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

William Hooten, M.D.

Contact us for the latest status

Contact information:

Danielle Zheng M.D., Ph.D.

(507)255-6219

Zheng.Danielle@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20467343

Mayo Clinic Footer